Osorio M.
67
Coauthors
5
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2020 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 9 |
| Inmunología | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 5 |
| Farmacología y terapéutica | 4 |
| Medicina y salud | 2 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 5 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Tania Crombet | 4 |
| Carmen Elena Viada | 2 |
| Pérez R. | 2 |
| Ramos M. | 2 |
| Cruz T. | 2 |
| Cepeda M. | 1 |
| Pérez K. | 1 |
| De La Torre A.V. | 1 |
| Saurez G. | 1 |
| Carr A. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
ArticleAbstract: Background: The role that growth factors and their receptors play in human cancer growth and progresPalabras claves:cancer vaccine, Epidermal growth factor, Non-small-cell lung cancerAutores:Alfonso L., Catala M., García Verdecia B., González G., Lage R., Mulet A., Neninger Vinageras E., Osorio M., Pérez R., Tania Crombet, Torres F.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusEffect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
ArticleAbstract: NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target forPalabras claves:Clinical trial, Ganglioside, melanoma, N-glycolyl GM3, Therapeutic vaccineAutores:Ávila Y., Carmen Elena Viada, Carr A., Cepeda M., De La Torre A.V., Fernandez L.E., Gracia E., Hernandez J., Osorio M., Pérez K., Reigosa E., Rodríguez M., Saurez G.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopusPharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study
ArticleAbstract: Purpose: To assess the pharmacodynamic effects of nimotuzumab, an anti-epidermal growth factor recepPalabras claves:Autores:Albanell J., Bellosillo B., Campas C., Cedeño M., Corominas J.M., Corradino I., Cruz T., Gascon P., Gracias E., Iznaga N., Marsoni S., Osorio M., Rojo F., Rovira A., Serrano S., Sessa C., Tania Crombet, Villena N.Fuentes:scopus